SIADH
MCID: SYN046
MIFTS: 44

Syndrome of Inappropriate Antidiuretic Hormone (SIADH)

Categories: Endocrine diseases, Rare diseases

Aliases & Classifications for Syndrome of Inappropriate Antidiuretic Hormone

MalaCards integrated aliases for Syndrome of Inappropriate Antidiuretic Hormone:

Name: Syndrome of Inappropriate Antidiuretic Hormone 53
Inappropriate Adh Syndrome 53 72
Dilutional Hyponatremia 53 72
Siadh 53 55
Syndrome of Inappropriate Antidiuretic Hormone Secretion 53
Schwartz Bartter Syndrome 53

Classifications:



External Ids:

UMLS 72 C0021141 C0585109

Summaries for Syndrome of Inappropriate Antidiuretic Hormone

NIH Rare Diseases : 53 Syndrome of inappropriate antidiuretic hormone (SIADH) occurs when an excessive amount of antidiuretic hormone is released resulting in water retention and a low sodium level. It is most common among older people. It has many causes including, but not limited too, pain, stress, exercise, a low blood sugar level, certain disorders of the heart, thyroid gland, kidneys, or adrenal glands, and the use of certain medications. Disorders of the lungs and certain cancers may increase the risk of developing SIADH. Treatment includes fluid restriction and sometimes the use of medications that decrease the effect of antidiuretic hormone on the kidneys.

MalaCards based summary : Syndrome of Inappropriate Antidiuretic Hormone, also known as inappropriate adh syndrome, is related to nephrogenic syndrome of inappropriate antidiuresis and inappropriate adh syndrome, and has symptoms including polyuria An important gene associated with Syndrome of Inappropriate Antidiuretic Hormone is AVP (Arginine Vasopressin), and among its related pathways/superpathways are Aquaporin-mediated transport and G alpha (s) signalling events. The drugs Tolvaptan and Natriuretic Agents have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and pituitary, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Syndrome of Inappropriate Antidiuretic Hormone

Diseases related to Syndrome of Inappropriate Antidiuretic Hormone via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 479)
# Related Disease Score Top Affiliating Genes
1 nephrogenic syndrome of inappropriate antidiuresis 32.7 AVPR2 AVP
2 inappropriate adh syndrome 32.3 POMC AVPR2 AVP AQP2
3 congestive heart failure 30.9 NPPB NPPA ACE
4 syncope 30.8 NPPB NPPA
5 malignant hypertension 30.8 NPPA ACE
6 granulomatous angiitis 30.8 AVP ACE
7 small cell cancer of the lung 30.7 POMC CHGA AVP
8 acute myocardial infarction 30.4 NPPB NPPA ACE
9 pure autonomic failure 30.2 NPPA ACE
10 lung oat cell carcinoma 30.1 POMC CHGA AVP
11 cervix small cell carcinoma 30.1 POMC CHGA AVP
12 hypokalemia 30.0 POMC AQP2 ACE
13 myocardial infarction 30.0 NPPB NPPA ALB ACE
14 pulmonary hypertension 29.9 NPPB NPPA ACE
15 heart disease 29.9 NPPB NPPA ALB ACE
16 acute kidney failure 29.8 NPPA ALB
17 dilated cardiomyopathy 29.7 NPPB NPPA ALB ACE
18 diabetes insipidus, nephrogenic, autosomal 29.6 AVPR2 AVP AQP2
19 cardiac arrest 29.6 NPPB AVP ALB ACE
20 liver cirrhosis 29.6 NPPA AVP AQP2 ALB
21 diabetes insipidus 29.5 POMC AVPR2 AVP AQP2
22 hypertension, essential 29.5 NPPB NPPA ALB ACE
23 hepatorenal syndrome 29.4 NPPA AQP2 ALB ACE
24 polycystic kidney disease 29.4 AVPR2 AQP2 ACE
25 autosomal dominant polycystic kidney disease 28.4 AVPR2 AVP AQP2 ALB ACE
26 myxedema 10.6 NPPA AVP
27 cardiac tamponade 10.6 NPPB AVP
28 central sleep apnea 10.6 NPPB NPPA
29 benign essential hypertension 10.6 AVP ALB
30 small cell carcinoma 10.6
31 vasculogenic impotence 10.5 NPPA ACE
32 mitral valve stenosis 10.5 NPPB NPPA
33 loeffler syndrome 10.5 ALB ACE
34 constrictive pericarditis 10.5 NPPB ALB
35 left bundle branch hemiblock 10.5 NPPB ACE
36 neuroendocrine carcinoma 10.5
37 herpes zoster 10.5
38 tricuspid valve insufficiency 10.5 NPPB ALB
39 orthostatic proteinuria 10.5 ALB ACE
40 ocular motor apraxia 10.5
41 aortic valve insufficiency 10.5 NPPB ACE
42 lambert-eaton myasthenic syndrome 10.5
43 hypertensive nephropathy 10.5 ALB ACE
44 anuria 10.5 ALB ACE
45 olfactory neuroblastoma 10.4
46 paraneoplastic syndromes 10.4
47 microvascular complications of diabetes 3 10.4 ALB ACE
48 systolic heart failure 10.4 NPPB ACE
49 central nervous system germinoma 10.4 POMC AVP
50 acute kidney tubular necrosis 10.4 NPPA ALB

Graphical network of the top 20 diseases related to Syndrome of Inappropriate Antidiuretic Hormone:



Diseases related to Syndrome of Inappropriate Antidiuretic Hormone

Symptoms & Phenotypes for Syndrome of Inappropriate Antidiuretic Hormone

UMLS symptoms related to Syndrome of Inappropriate Antidiuretic Hormone:


polyuria

MGI Mouse Phenotypes related to Syndrome of Inappropriate Antidiuretic Hormone:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.7 ACE APLN AQP2 AVP AVPR2 POMC
2 homeostasis/metabolism MP:0005376 9.65 ACE ALB APLN AQP2 AVP AVPR2
3 renal/urinary system MP:0005367 9.23 ACE ALB AQP2 AVP AVPR2 CHGA

Drugs & Therapeutics for Syndrome of Inappropriate Antidiuretic Hormone

Drugs for Syndrome of Inappropriate Antidiuretic Hormone (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tolvaptan Approved Phase 4 150683-30-0 216237
2 Natriuretic Agents Phase 4
3 Antidiuretic Hormone Receptor Antagonists Phase 4
4 Hormones Phase 4
5 Vasopressins Phase 4
6 Arginine Vasopressin Phase 4
7 Liver Extracts Phase 4
8
Mercaptopurine Approved Phase 3 50-44-2 667490
9
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
10
Pegaspargase Approved, Investigational Phase 3 130167-69-0
11
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
leucovorin Approved Phase 3 58-05-9 143 6006
14
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
15
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
16
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
17
Etoposide Approved Phase 3 33419-42-0 36462
18
Lenograstim Approved, Investigational Phase 3 135968-09-1
19
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
20
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
21
Empagliflozin Approved Phase 2, Phase 3 864070-44-0
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23
Aspartic acid Approved, Nutraceutical Phase 3 56-84-8 5960
24
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
25
Satavaptan Investigational Phase 3 185913-78-4 7029
26 Coagulants Phase 3
27 Hemostatics Phase 3
28 Hormone Antagonists Phase 3
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
30 Vasoconstrictor Agents Phase 3
31 Deamino Arginine Vasopressin Phase 2, Phase 3
32 Antiemetics Phase 3
33 Tubulin Modulators Phase 3
34 Folic Acid Antagonists Phase 3
35 Gastrointestinal Agents Phase 3
36 Antidotes Phase 3
37
Liposomal doxorubicin Phase 3 31703
38 N-Methylaspartate Phase 3
39 Antineoplastic Agents, Phytogenic Phase 3
40 Peripheral Nervous System Agents Phase 3
41 glucocorticoids Phase 3
42 Anti-Inflammatory Agents Phase 3
43 Vitamin B9 Phase 3
44 Folate Phase 3
45 Anti-Infective Agents Phase 3
46 Anti-Bacterial Agents Phase 3
47 Antineoplastic Agents, Hormonal Phase 3
48 Nucleic Acid Synthesis Inhibitors Phase 3
49 Vitamin B Complex Phase 3
50 Antibiotics, Antitubercular Phase 3

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
2 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
3 Assessment of Clinical Outcome and Treatment Quality Under Adequate Use of Tolvaptan In Correction of Hyponatremia in Patients Hospitalized With Worsening Heart Failure and Hyponatremia Terminated NCT02352285 Phase 4 Tolvaptan;Placebo
4 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
5 Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine Withdrawn NCT00298753 Phase 4
6 A Multicenter, Randomized, Double-blind, Placebo-controlled (Standard Therapy + Placebo) Study to Evaluate the Efficacy and Safety of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia Unknown status NCT01507727 Phase 2, Phase 3 Tolvaptan;Placebo
7 A Randomized, Double-Blind, Placebo-Group, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264927 Phase 3 SR121463B
8 An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT00264914 Phase 3 SR121463B
9 Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study Completed NCT02729766 Phase 2, Phase 3 Empagliflozin 25mg Tbl;Placebo P-Tablet
10 Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies Completed NCT00381680 Phase 3 vincristine sulfate;prednisone;doxorubicin hydrochloride;pegaspargase;cytarabine;methotrexate;dexamethasone;etoposide;cyclophosphamide;leucovorin calcium;asparaginase;mercaptopurine
11 A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients With Dilutional Hyponatremia Completed NCT00274326 Phase 3 SR121463B
12 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia Completed NCT00660959 Phase 3 lixivaptan;placebo
13 Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study Completed NCT02874807 Phase 2, Phase 3 Empagliflozin
14 Multicenter, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia, Study 2 Completed NCT00201994 Phase 3 Tolvaptan
15 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia Completed NCT00072683 Phase 3 tolvaptan
16 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia Completed NCT00876798 Phase 3 Lixivaptan;Placebo
17 A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Recruiting NCT03048747 Phase 3 Tolvaptan Oral Tablet
18 Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study Recruiting NCT03202667 Phase 2, Phase 3 Empagliflozin 25mg;Placebo
19 A Double-Blind, Randomized, Placebo-Controlled Multicenter Study Evaluating the Efficacy and Safety of Two Doses of Satavaptan (SR121463B) Versus Placebo in Patients With Dilutional Hyponatremia Due to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) Terminated NCT00728091 Phase 3 Satavaptan;placebo
20 Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA(r) (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized With Dilutional Hyponatremia Terminated NCT01227512 Phase 3 tolvaptan
21 A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA ® (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects Hospitalized With Euvolemic or Hypervolemic Hyponatremia Terminated NCT02012959 Phase 3 Tolvaptan
22 A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan) Terminated NCT02020278 Phase 3 Tolvaptan
23 A Pilot Phase 3b,Multicenter,Randomized,Double-blind,Placebo-controlled Trial of the Safety,Efficacy,and Pharmacokinetics of Titrated Oral SAMSCA®(Tolvaptan) in Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Withdrawn NCT02442674 Phase 3 Tolvaptan
24 Hematological, Biochemical and Hemodynamic Changes During Operative Hysteroscopy Using Consecutive Distension Media Unknown status NCT03166228 Phase 2 Normal Saline 0.9% Infusion Solution Bag;1.5% Glycine only
25 A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed NCT02009878 Phase 1, Phase 2 tolvaptan
26 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation, Multicenter Study Evaluating the Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion. Completed NCT00032734 Phase 2 satavaptan (SR121463B)
27 Randomized, Double-blind, Multicenter, Placebo-controlled (Standard Therapy + Placebo), Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia Completed NCT00664014 Phase 2 Tolvaptan;Placebo
28 Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial Active, not recruiting NCT00278629 Phase 2
29 A Pilot Study To Evaluate The Incidence Of Hyponatremia In A Medical-Surgical Hospital And To Explore The Efficacy And Safety Of Tolvaptan In The Clinical Practice Terminated NCT01386372 Phase 2 Tolvaptan
30 Transplantation of Expanded and Unexpanded Umbilical Cord Blood Units Following Myeloablative Chemotherapy for Hematologic Malignancies Terminated NCT00539656 Phase 1, Phase 2
31 Hematopoietic Stem Cell Transplant in Patients With Refractory Sarcoidosis: A Phase I/II Trial Terminated NCT00282438 Phase 1, Phase 2
32 High Dose Immune Suppression With Hematopoietic Stem Cell Support in Refractory Vasculitis, Necrotizing Vasculitis, Neurovascular Behcet's Disease, and Sjogren's Syndrome Terminated NCT00278512 Phase 1 Cyclophosphamide;ATG (rabbit);G-CSF;Campath-1h;Fludarabine;Tacrolimus;Mesna
33 A Multi-Centre, Multi-National, Observational Post-Authorisation Safety Study to Document the Drug Utilisation of Samsca and to Collect Information on the Safety of Samsca When Used in Routine Medical Practice Unknown status NCT01228682 Tolvaptan
34 Comparison of Ringer Lactate and Isotonic Acetate Solution as Maintenance Fluids in Children Undergoing Elective Laparoscopic Surgery Unknown status NCT02936167
35 A Non Interventional, Retrospective Study on Real World Usage and Treatment Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to the SIADH. Completed NCT02545101
36 An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized With Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization Completed NCT01240668
37 An Observational, Retrospective Study to Describe the Extent of Adherence to the Spanish Society of Medical Oncology Algorithm for the Treatment of Hyponatraemia Secondary to SIADH in Oncology Patients in Spain (ALGA) Completed NCT02548845
38 A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia Secondary to SIADH in Italy Completed NCT02573077
39 Subclassification of the Syndrome of Inappropriate Antidiuresis Via Copeptin - What is the Genesis of ADH-independent SIADH? Completed NCT01341665
40 International, Multicenter Study of a Twenty-eight Week, Open-label, Titrated Oral Lixivaptan Administration in Patients With Chronic Hyponatremia: Extension to Studies CK-LX3401, 3405, and 3430 Completed NCT01056848
41 Copeptin as a Diagnostic Marker in the Management of Neurosurgical Patients With Disturbance of Water Homeostasis Completed NCT01465672
42 Phenotypic Characterization of Neuropsychologic and Physical Performance in Geriatric Patients Suffering From Hyponatremia. Completed NCT02242604
43 Spectrum of Serum Sodium Disturbances in Patients With Non-sellar/Suprasellar Supratentorial Tumors Completed NCT03570203
44 Disturbances of the Sodium and Fluid Balance in Patients With Severe Traumatic Brain Injury and Non-traumatic Subarachnoid Hemorrhage. A Systematic Observational Study Completed NCT01313975
45 Copeptin as a Novel Diagnostic and Prognostic Marker in the Management of Neurological and Neurosurgical Patients With Sodium Imbalance The "COSMOS"-Study (Copeptin in Osmoregulation and Stress Assessment) Completed NCT00390962
46 Prophylaxis Versus Treatment Against TURP Syndrome : Role of Hypertonic Saline Active, not recruiting NCT03428451 NaCl 3% HS;NaCl 3% HS;NaCl 0.9% NS
47 Standardization of Fluids in Inpatient Settings Active, not recruiting NCT03924674
48 Transthoracic Echocardiographic Evaluation of the Cardiac Function During Transurethral Resection of Prostate in Elderly Patients Terminated NCT02288780
49 Holmium Laser Ablation of the Prostate (HoLAP) Versus KTP Laser Vaporization of the Prostate: A Randomized Comparison Study Terminated NCT00169767
50 Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries Terminated NCT02545114 Tolvaptan

Search NIH Clinical Center for Syndrome of Inappropriate Antidiuretic Hormone

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Demeclocycline

Genetic Tests for Syndrome of Inappropriate Antidiuretic Hormone

Anatomical Context for Syndrome of Inappropriate Antidiuretic Hormone

MalaCards organs/tissues related to Syndrome of Inappropriate Antidiuretic Hormone:

41
Lung, Brain, Pituitary, Heart, Kidney, Prostate, Thyroid

Publications for Syndrome of Inappropriate Antidiuretic Hormone

Articles related to Syndrome of Inappropriate Antidiuretic Hormone:

(show top 50) (show all 1985)
# Title Authors PMID Year
1
Hyponatremia and brain injury: absence of alterations of serum brain natriuretic peptide and vasopressin. 9 38
20069215 2009
2
[Hyponatraemia in patients with neurosurgical disorders: SIADH or cerebral salt wasting syndrome?]. 9 38
19885796 2009
3
Intermittent severe, symptomatic hyponatraemia due to the nephrogenic syndrome of inappropriate antidiuresis. 9 38
18753429 2008
4
Severe paraneoplastic hyponatremia and hypoosmolality in a patient with small-cell lung carcinoma: syndrome of inappropriate antidiuretic hormone secretion versus atrial natriuretic peptide or both? 9 38
17562242 2007
5
A rare case of combined syndrome of inappropriate antidiuretic hormone secretion and Fanconi syndrome in an elderly woman. 9 38
16797399 2006
6
Atrial natriuretic peptide in children with pneumonia. 9 38
15830390 2005
7
Hypothalamic-pituitary-adrenal axis and interleukin-6 activity in children with head trauma and syndrome of inappropriate secretion of antidiuretic hormone. 9 38
12585340 2003
8
Aquaporins in the kidney: from molecules to medicine. 9 38
11773613 2002
9
Physiology and pathophysiology of renal aquaporins. 9 38
11320486 2001
10
Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects. 9 38
11297601 2001
11
[New players in the physiopathology of water metabolism: the aquaporins]. 9 38
10667046 1999
12
[Severe peripheral neuropathy, cardiac hypofunction, and syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a patient with Churg-Strauss syndrome]. 9 38
10614173 1999
13
Syndrome of inappropriate antidiuretic hormone secretion in children following spinal fusion. 9 38
10199545 1999
14
Long-term regulation of urinary concentrating capacity. 9 38
9729504 1998
15
Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). 9 38
9100572 1997
16
Pathogenesis of hyponatremia following subarachnoid hemorrhage due to ruptured cerebral aneurysm. 9 38
8874554 1996
17
Early diagnosis of ectopic arginine vasopressin secretion. 9 38
8380364 1993
18
Ectopic atrial natriuretic peptide production in small cell lung cancer with the syndrome of inappropriate antidiuretic hormone secretion. 9 38
1655209 1991
19
[Syndrome of inappropriate ADH secretion (SIADH) in small-cell bronchus carcinoma]. 9 38
1656520 1991
20
A case of syndrome of inappropriate secretion of antidiuretic hormone associated with diabetes mellitus. 9 38
1794339 1991
21
Corticotropin deficiency: a rare cause of hyponatremia mimicking SIADH. 9 38
1648196 1991
22
Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus. 9 38
2139879 1990
23
Hyponatremia in children under 100 days old: incidence and etiologies. 38
31300884 2019
24
Hyponatremia in patients with cancer. 38
31232709 2019
25
Hyponatremia After Spontaneous Aneurysmal Subarachnoid Hemorrhage-A Prospective Observational Study. 38
31154098 2019
26
Clinical approach to sodium homeostasis disorders in children with pituitary-suprasellar tumors. 38
31401632 2019
27
A quantitative approach to intravenous fluid therapy in the syndrome of inappropriate antidiuretic hormone secretion. 38
31049746 2019
28
Acromegaly remission, SIADH and pituitary function recovery after macroadenoma apoplexy 38
31310082 2019
29
Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes. 38
31297663 2019
30
Severe presentation of antibody-negative, postinfectious steroid-responsive encephalitis and atonic bladder after herpes simplex encephalitis. 38
31337628 2019
31
Cerebral salt wasting in a patient with myeloproliferative neoplasm. 38
31319788 2019
32
Serum Na+ Level in Children Suffering from Acute Bronchiolitis: A Review. 38
31391452 2019
33
Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis. 38
31004513 2019
34
Amiodarone-Induced Syndrome of Inappropriate Antidiuretic Hormone: A Case Report and Review of the Literature. 38
31258313 2019
35
Paraneoplastic syndromes and other systemic disorders associated with neuroendocrine neoplasms. 38
30910348 2019
36
Neonatal Encephalopathy and SIADH during RSV Infection. 38
31238369 2019
37
Acute Hyponatremia Resulting from Duloxetine-induced Syndrome of Inappropriate Antidiuretic Hormone Secretion. 38
30799365 2019
38
Syndrome of inappropriate antidiuretic hormone secretion following transarterial chemoembolisation of hepatocellular carcinoma. 38
31167725 2019
39
Syndrome of inappropriate antidiuretic hormone secretion and Leser-Trélat syndrome as uncommon paraneoplastic manifestations of renal malignancy - a geriatric experience: a case report. 38
31221202 2019
40
Duloxetine and Angiotensin II Receptor Blocker Combination Potentially Induce Severe Hyponatremia in an Elderly Woman. 38
30799349 2019
41
A Rare Case of Syndrome of Inappropriate Anti-diuretic Hormone in Non-small Cell Lung Cancer Presenting as Superior Vena Cava Syndrome. 38
31410343 2019
42
Posterior pituitary dysfunction following traumatic brain injury: review. 38
30334138 2019
43
CLINICAL PRACTICE PATTERNS FOR POSTOPERATIVE WATER BALANCE AFTER PITUITARY SURGERY. 38
31170367 2019
44
The prevalence of sodium abnormalities in moderate to severe traumatic brain injury patients in a level 1 Trauma unit in Durban. 38
31342687 2019
45
Tolvaptan-induced Liver Injury: Who is at Risk? A Case Report and Literature Review. 38
31410325 2019
46
Hyponatremia secondary to transient renal salt wasting (TRSW): A not so uncommon observation in the elderly
. 38
30935460 2019
47
Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database. 38
30977109 2019
48
Talaromyces marneffei laboratory cross reactivity with Histoplasma and Blastomyces urinary antigen. 38
31229614 2019
49
Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for Craniopharyngioma 38
30257818 2019
50
A Study of Hyponatremia in Acute Encephalitis Syndrome: A Prospective Study From a Tertiary Care Center in India. 38
28393593 2019

Variations for Syndrome of Inappropriate Antidiuretic Hormone

Expression for Syndrome of Inappropriate Antidiuretic Hormone

Search GEO for disease gene expression data for Syndrome of Inappropriate Antidiuretic Hormone.

Pathways for Syndrome of Inappropriate Antidiuretic Hormone

GO Terms for Syndrome of Inappropriate Antidiuretic Hormone

Cellular components related to Syndrome of Inappropriate Antidiuretic Hormone according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 POMC NPPB NPPA CHGA AVP APLN
2 secretory granule GO:0030141 9.33 POMC CHGA AVP
3 transport vesicle membrane GO:0030658 9.32 CHGA AQP2
4 mast cell granule GO:0042629 9.26 NPPA CHGA
5 extracellular space GO:0005615 9.23 POMC NPPB NPPA CHGA AVP APLN

Biological processes related to Syndrome of Inappropriate Antidiuretic Hormone according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of vasoconstriction GO:0045907 9.51 AVPR2 AVP
2 positive regulation of blood pressure GO:0045777 9.49 AVPR2 ACE
3 regulation of the force of heart contraction GO:0002026 9.48 CHGA APLN
4 water transport GO:0006833 9.46 AVP AQP2
5 regulation of blood vessel diameter GO:0097746 9.43 NPPB ACE
6 renal water homeostasis GO:0003091 9.43 AVPR2 AVP AQP2
7 receptor guanylyl cyclase signaling pathway GO:0007168 9.4 NPPB NPPA
8 positive regulation of cardiac muscle contraction GO:0060452 9.37 NPPA CHGA
9 regulation of blood vessel size GO:0050880 9.33 NPPB NPPA AVP
10 cGMP biosynthetic process GO:0006182 9.32 NPPB NPPA
11 excretion GO:0007588 9.22 AVPR2
12 positive regulation of systemic arterial blood pressure GO:0003084 9.13 AVPR2 AVP ACE
13 regulation of blood pressure GO:0008217 9.02 POMC NPPB NPPA CHGA ACE

Molecular functions related to Syndrome of Inappropriate Antidiuretic Hormone according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.35 POMC NPPB NPPA AVP APLN
2 neuropeptide hormone activity GO:0005184 9.26 NPPA AVP
3 hormone receptor binding GO:0051427 9.16 NPPB NPPA
4 hormone activity GO:0005179 9.02 POMC NPPB NPPA AVP APLN

Sources for Syndrome of Inappropriate Antidiuretic Hormone

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....